JP2022538576A5 - - Google Patents

Info

Publication number
JP2022538576A5
JP2022538576A5 JP2021576779A JP2021576779A JP2022538576A5 JP 2022538576 A5 JP2022538576 A5 JP 2022538576A5 JP 2021576779 A JP2021576779 A JP 2021576779A JP 2021576779 A JP2021576779 A JP 2021576779A JP 2022538576 A5 JP2022538576 A5 JP 2022538576A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
chloro
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021576779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538576A (ja
JP7498199B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/055974 external-priority patent/WO2020261144A1/en
Publication of JP2022538576A publication Critical patent/JP2022538576A/ja
Publication of JP2022538576A5 publication Critical patent/JP2022538576A5/ja
Application granted granted Critical
Publication of JP7498199B2 publication Critical patent/JP7498199B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021576779A 2019-06-28 2020-06-24 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体 Active JP7498199B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962868542P 2019-06-28 2019-06-28
US62/868,542 2019-06-28
US202062960824P 2020-01-14 2020-01-14
US62/960,824 2020-01-14
PCT/IB2020/055974 WO2020261144A1 (en) 2019-06-28 2020-06-24 5-(thiophen-2-yl)-1h-tetrazole derivatives as bckdk inhibitors useful for treating various diseases

Publications (3)

Publication Number Publication Date
JP2022538576A JP2022538576A (ja) 2022-09-05
JP2022538576A5 true JP2022538576A5 (enExample) 2023-06-02
JP7498199B2 JP7498199B2 (ja) 2024-06-11

Family

ID=71738227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021576779A Active JP7498199B2 (ja) 2019-06-28 2020-06-24 種々の疾患を処置するために有用なｂｃｋｄｋ阻害剤としての５－（チオフェン－２－イル）－１ｈ－テトラゾール誘導体

Country Status (5)

Country Link
US (1) US20220363673A1 (enExample)
EP (1) EP3990452A1 (enExample)
JP (1) JP7498199B2 (enExample)
CA (1) CA3144848C (enExample)
WO (1) WO2020261144A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312296A (en) * 2021-12-01 2024-06-01 Pfizer 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
CN116574084A (zh) * 2023-04-17 2023-08-11 华南理工大学 一种噻吩衍生物及其合成方法与应用
AU2025209211A1 (en) 2024-01-18 2026-07-30 Tuojie Biotech (Shanghai) Co., Ltd. Pyridothiophene-2-carboxylic acid derivative, preparation method therefor and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3438830A1 (de) 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
JP3265680B2 (ja) 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19504832A1 (de) 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ID26984A (id) 1998-07-06 2001-02-22 Bristol Myers Squibb Co Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
DE10306502B4 (de) 2003-02-17 2005-03-17 Aventis Pharma Deutschland Gmbh Substituierte 3-(Benzoylureido)-thiophenderivate und sie enthaltende Arzneimittel
EA011086B9 (ru) 2004-05-12 2012-08-30 Пфайзер Продактс Инк. Производные пролина и их применение в качестве ингибиторов дипептидилпептидазы iv
EP2010520B1 (en) 2006-04-20 2012-09-12 Pfizer Products Inc. Heterobicyclic amides for the prevention and treatment of glucokinase-mediated diseases
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
CN102066365A (zh) 2008-06-19 2011-05-18 米伦纽姆医药公司 噻吩或噻唑衍生物和其作为pi3k抑制剂的用途
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
ES2380408T3 (es) 2008-08-28 2012-05-11 Pfizer Inc. Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010034358A1 (en) 2008-09-29 2010-04-01 Nokia Siemens Networks Oy Apparatus, method, system and program for power control or power setting
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
WO2010103437A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Benzofuranyl derivatives used as glucokinase inhibitors
CA2754523A1 (en) 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
EP2427448A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
GEP20135907B (en) 2009-06-05 2013-08-12 Pfizer L-(piperidin-4-yl)-pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
WO2011073298A1 (en) 2009-12-18 2011-06-23 Neurosearch A/S Tetrazole derivatives as nicotinic acetylcholine receptor modulators
EP2681208B1 (en) 2011-03-03 2016-05-18 Denovamed Inc. Antimicrobial/adjuvant compounds
CN108779495A (zh) * 2016-04-06 2018-11-09 雀巢产品技术援助有限公司 调节bckdh的方法
WO2018109607A1 (en) 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof

Similar Documents

Publication Publication Date Title
JP2022540000A5 (enExample)
ES3025032T7 (en) Carboxy-benzimidazole glp-1r modulating compounds
CN101903356B (zh) 4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
US8569339B2 (en) Soluble guanylate cyclase activators
US20200347016A1 (en) Substituted pyrrolidines as g-protein coupled receptor 43 agonists
US9150575B2 (en) Piperidinylpyrazolopyridine derivative
TWI780511B (zh) Trpc 6抑制劑
US20100190980A1 (en) Pyrazinamide compound
CN114728168A (zh) 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
HRP20230631T1 (hr) Agonisti receptora glp-1 i njihova upotreba
JP2017515836A5 (enExample)
JP5301456B2 (ja) ヘテロアリールオキシキナゾリン誘導体
JP2020521730A5 (enExample)
IL310377A (en) Novel aryl ether substituted heterocyclic compound as glp1r agonist
US9340506B2 (en) Acetamide derivatives as glucokinase activators, their process and medicinal applications
IL319486A (en) HSD17B13 Inhibitors and/or Retarders
JP2016530299A5 (enExample)
JP2011502982A5 (enExample)
AU2015313829A1 (en) Fused heterocyclic compounds as GPR120 agonists
TW202539631A (zh) 使用葡萄糖依賴性促胰島素多肽受體拮抗劑化合物及glp-1受體促效劑化合物之組合療法
WO2012129967A1 (zh) 新型胺基吡啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
RU2024114883A (ru) Производные 3-фенил-1-бензотиофен-2-карбоновой кислоты в качестве ингибиторов киназы дегидрогеназы альфа-кетокислот с разветвленной цепью для лечения диабета, заболеваний почек, nash и сердечной недостаточности
TW201039827A (en) Indoline compound
JP5583841B2 (ja) 新規なフェニルピリジン誘導体及びこれを含有する医薬
IL319392A (en) Pectin-like phospholipase domain-containing protein 3 (PNPLA3) modification preparations